drugset / Trial / NCT00999544
Aprepitant Effects on Oxycodone Response
Completed
9 enrolled
Sharon Walsh
Merck Sharp & Dohme LLC · collabNational Institute on Drug Abuse (NIDA) · collab
RandomizedCrossoverTriple-blindBasic science
Summary
Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects.
Timeline
- Start
- 2009-10
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 40 mg | Oral |
| Subject | Aprepitant | Other / unclassified | 200 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 15 mg | Intranasal |
| Subject | Oxycodone | Other / unclassified | 20 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 30 mg | Intranasal |
| Subject | Oxycodone | Other / unclassified | 40 mg | Oral |